A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies
Latest Information Update: 28 Jan 2026
At a glance
- Drugs KPL 387 (Primary)
- Indications Pericarditis
- Focus Therapeutic Use
- Sponsors Kiniksa Pharmaceuticals
Most Recent Events
- 22 Dec 2025 New trial record